Purpose: To validate the independent strong prognostic value of mitotic activity index (MAI) in lymph node (LN) –negative invasive breast cancer patients younger than 55 years in a nationwide multicenter prospective study. Patients and Methods: Analysis of routinely assessed MAI and other prognosticators in 516 patients (median follow-up, 118 months; range, 8 to 185 months), without systemic adjuvant therapy or previous malignancies. Results: Distant metastases occurred in 127 patients (24.6%); 90 (17.4%) died as a result of metastases. MAI (< 10, ≥ 10) showed strong association with recurrence (hazard ratio [HR],3.12; 95% CI, 2.17 to 4.50; P ≤ .0001) and mortality (HR, 4.42; 95% CI, 2.79 to 7.01; P < .0001). The absolute difference in 10...
Proliferation, either as the main common denominator in genetic profiles, or in the form of single f...
Background: The study was designed in order to evaluate the degree of correlation of mitotic index (...
PURPOSE: To identify groups of early breast cancer patients with substantial risk (10-year risk > 20...
Purpose: To validate the independent strong prognostic value of mitotic activity index (MAI) in lymp...
PURPOSE: To validate the independent strong prognostic value of mitotic activity index (MAI) in lymp...
BACKGROUND: At the St Gallen meeting of 2001 it was agreed to select high-risk patients for adjuvant...
Purpose: The aim of this study is to evaluate the prognostic value of the Mitotic Activity Index (MA...
The aim of the present study is to look at the mitotic activity index (MAI) as a prognostic factor i...
The proliferation marker mitotic activity index is the strongest prognostic indicator in lymph node-...
Contains fulltext : 88107.pdf (publisher's version ) (Closed access)We evaluated w...
Background: The prognostic value of the PI3K/Akt/mTOR pathway and PTEN in invasive breast cancer (IB...
Contains fulltext : 144217.pdf (publisher's version ) (Closed access)AIMS: The Mit...
Item does not contain fulltextNode-negative breast cancer patients have a relatively good prognosis,...
We evaluated with long-term follow-up, the prognostic value of the mitotic activity index (MAI) and ...
Proliferation, either as the main common denominator in genetic profiles, or in the form of single f...
Proliferation, either as the main common denominator in genetic profiles, or in the form of single f...
Background: The study was designed in order to evaluate the degree of correlation of mitotic index (...
PURPOSE: To identify groups of early breast cancer patients with substantial risk (10-year risk > 20...
Purpose: To validate the independent strong prognostic value of mitotic activity index (MAI) in lymp...
PURPOSE: To validate the independent strong prognostic value of mitotic activity index (MAI) in lymp...
BACKGROUND: At the St Gallen meeting of 2001 it was agreed to select high-risk patients for adjuvant...
Purpose: The aim of this study is to evaluate the prognostic value of the Mitotic Activity Index (MA...
The aim of the present study is to look at the mitotic activity index (MAI) as a prognostic factor i...
The proliferation marker mitotic activity index is the strongest prognostic indicator in lymph node-...
Contains fulltext : 88107.pdf (publisher's version ) (Closed access)We evaluated w...
Background: The prognostic value of the PI3K/Akt/mTOR pathway and PTEN in invasive breast cancer (IB...
Contains fulltext : 144217.pdf (publisher's version ) (Closed access)AIMS: The Mit...
Item does not contain fulltextNode-negative breast cancer patients have a relatively good prognosis,...
We evaluated with long-term follow-up, the prognostic value of the mitotic activity index (MAI) and ...
Proliferation, either as the main common denominator in genetic profiles, or in the form of single f...
Proliferation, either as the main common denominator in genetic profiles, or in the form of single f...
Background: The study was designed in order to evaluate the degree of correlation of mitotic index (...
PURPOSE: To identify groups of early breast cancer patients with substantial risk (10-year risk > 20...